Portfolio

HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).  This designation is for the proposed Eye90 microspheres indication for the treatment of …

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) Read More »

Glucksmann succeeds current Sensorium CEO and Co-Founder Dick Simon, who will transition to an advisory role and continue to serve on the Board of Directors The company announces a $3 million National Institutes of Health/National Institute on Aging grant to expand the capabilities of its nature-inspired approach/platform to address Alzheimer’s-related dementia Company progresses its platform and lead candidate, SENS-01, …

Sensorium Therapeutics Announces Appointment of Veteran Biotech Executive Alexandra Glucksmann, Ph.D., as CEO as the Company Progresses Toward the Clinic Read More »

Santé Ventures was the sole venture capital investor in Laminar, which aims to treat persistent atrial fibrillation (AFib) with an innovative solution for the left atrial appendage (LAA) AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ — Santé Ventures (Santé), an early-stage healthcare and life sciences investment firm, has announced the acquisition of its Fund III portfolio company, Laminar, Inc., by …

Laminar, Inc. Acquired by Johnson & Johnson Medtech for $400 Million Upfront with Additional Clinical and Regulatory Milestone Payments in 2024 and Beyond Read More »

NEW YORK – Geneos Therapeutics has set out to prove that cancer vaccines can do more than prevent disease recurrence in the adjuvant setting, and in a Phase I/IIa trial, the firm wants to show that its personalized DNA vaccine GNOS-PV02 can also treat advanced tumors. In August, Geneos reported data from the GT-30 trial showing that …

Geneos Therapeutics’ Cancer Vaccine Shows Potential for Shrinking ‘Difficult’ Tumors Read More »

A new Duke study shows that KelaHealth’s platform was associated with a 21% reduction in acute kidney injury and a 24% decrease in costly readmissions following colorectal surgery. The platform delivers insights about individual patients’ surgical risks and what their care journeys should look like.   The digital health market is full of companies promising …

How KelaHealth Slashed the Rate of Post-Surgical Complications at Duke Read More »

ENGULF Study utilizing next generation technology in targeting pulmonary embolism  Menlo Park, Calif., October 31, 2023 – Endovascular Engineering (“E2”), a mission driven,  venture-backed, medical device company focused on the development and deployment of next  generation clot removal technologies, announced today positive initial results from its ENGULF  study. The study demonstrated successful outcomes among the …

Endovascular Engineering, Inc. Announces Positive Initial Results in ENGULF Study for HēloTM Thrombectomy System Read More »

HALIFAX, NS, Oct. 24, 2023 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the first patient treated in its Route90 US IDE Pivotal study. The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology in Charlotte NC. …

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma Read More »

Greater Houston health system’s investment to expand technology-enabled services platform to help deliver high quality oncology care from the comfort of home Reimagine Care, the nation’s leading provider of virtual and at-home cancer care services, is pleased to announce an investment from Memorial Hermann Health System, a non-profit, community-focused, award-winning health system committed to creating …

Reimagine Care Announces Investment from Memorial Hermann to Help Transform the Cancer Care and Recovery Experience Read More »

Taking a page from the airline industry, hospitals are capturing surgical procedures on video to reduce errors and enhance teamwork. Here’s why one expert thinks black boxes are crucial for improving patient safety. By Mary Hawn, MD, MPH Mary Hawn, MD, MPH, and a colleague perform surgery at Stanford Hospital in Palo Alto, California, under the …

Why every operating room needs a black box Read More »

Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer Shanghai-based SHC Added to Geneos’ Investor Syndicate PLYMOUTH MEETING, Pa., Sept. 27, 2023 /PRNewswire/ — Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing …

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million Read More »

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) — Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer …

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors Read More »

Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, appointed Philip Vickers, President, and Chief Executive Officer. Vickers succeeds David Donabedian, co-founder, and start-up CEO of the company. Vickers has more than 30 years of experience in the biopharma industry. As CEO, he will play an instrumental role in the company’s work to eliminate …

Solu Therapeutics Names Philip Vickers President and CEO Read More »

Planned Leadership Transition to Accelerate the Company’s Next Stage of Growth; Founding CEO Ashish Nimgaonkar, M.D., Transitions to Chief Medical Officer and Head of R&D Lead Candidate, GLY-200, Ready to Begin Phase 2b Development for Obesity and Type 2 Diabetes BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, …

Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer Read More »

On August 28, 2023, Boston Scientific unveiled its revolutionary Farapulse Pulsed Field Ablation system, a cutting-edge therapy designed to selectively ablate heart tissue in atrial fibrillation patients. This groundbreaking technology has been proven to be as effective as the current standard-of-care treatments, radiofrequency, and cryoablation, as demonstrated by the ADVENT study. The promising results from this study are expected …

Boston Scientifics Farapulse Pulsed Field Ablation System Revolutionizing Cardiac Care Read More »

By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date Three of the Seven Patients With Durable Partial Responses, and One With Stable Disease, Have Now Achieved Complete Molecular Response By Ultrasensitive ctDNA Analysis  No Serious Adverse Events Related to Cancer Vaccine, Related Adverse Events Grades 1 and 2 Only PLYMOUTH MEETING, …

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer Read More »

Boston Scientific’s Farapulse pulsed-field ablation (PFA) system likely hit its primary endpoints, according to Needham analysts who say that means the technology is poised for FDA approval. Boston Scientific has already said it expects FDA approval of Farapulse next year, but has not yet shared results from its ADVENT pivotal trial. That data is set …

Boston Scientific’s Farapulse PFA system is poised for FDA approval, analysts say Read More »

CareHive, a leader in the health technology landscape, is transforming healthcare delivery through its pioneering 3-pronged technology approach — an initiative designed to revolutionize healthcare plans, amplify patient care, and support at-risk providers. Houston, TX – CareHive, a leader in the health technology landscape, is transforming healthcare delivery through its pioneering 3-pronged technology approach — an initiative designed …

CareHive continues to lead the way with 3-pronged technology approach – For Health plans, patients, and at-risk providers Read More »

Clinical candidate selected, initially targeting hematological malignancies BOSTON–(BUSINESS WIRE)–Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced the closing of an oversubscribed $31 million seed financing co-led by Longwood and Santé Ventures, with additional participation from DCVC Bio, Astellas Venture Management, and Alexandria Venture Investments. The proceeds …

Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets Read More »

Nomination Recognizes Progress and Promise of Geneos’ Personalized Therapeutic Cancer Vaccines PLYMOUTH MEETING, Pa., July 28, 2023 /PRNewswire/ — Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has been nominated for the Prix Galien Startup Award for 2023. The Galien Foundation is the premier global …

Geneos Therapeutics Nominated for 2023 Prix Galien USA Startup Award Read More »

Obesity has nearly tripled since 1975, becoming an ever-growing health threat. In 2016, it was estimated that more than 1.9 billion adults in the world were overweight, with more than 650 million of those being officially obese.  Obesity can be defined as abnormal or excessive fat accumulation that presents a risk to health, with a …

New weight loss drugs: biotech’s mission to end obesity Read More »